Search

Your search keyword '"Alonso, Rafael"' showing total 8 results
Start Over Author "Alonso, Rafael" Publication Year Range This year
8 results on '"Alonso, Rafael"'

2. AUTO-DataGenCARS+: An Advanced User-Oriented Tool to Generate Data for the Evaluation of Recommender Systems

Author

del Carmen Rodríguez-Hernández, María, Ilarri, Sergio, Caballero, Marcos, Trillo-Lado, Raquel, Hermoso, Ramón, del-Hoyo-Alonso, Rafael, Goos, Gerhard, Series Editor, Hartmanis, Juris, Founding Editor, Bertino, Elisa, Editorial Board Member, Gao, Wen, Editorial Board Member, Steffen, Bernhard, Editorial Board Member, Yung, Moti, Editorial Board Member, Delir Haghighi, Pari, editor, Fedushko, Solomiia, editor, Kotsis, Gabriele, editor, and Khalil, Ismail, editor

Published
2025
Full Text
View/download PDF

5. Microbiota-derived urolithin A in monoclonal gammopathies and multiple myeloma therapy.

Author

Rodríguez-García, Alba, Ancos-Pintado, Raquel, García-Vicente, Roberto, Ortiz-Ruiz, Alejandra, Arroyo, Andrés, Navarro, Miguel Ángel, Morales, María Luz, Guevara-Ramirez, Patricia, Justo, Pablo, López-Muñoz, Nieves, Sánchez-Pina, José, Alonso, Rafael, Selma, María Victoria, Frutos-Lisón, María Dolores, García-Villalba, Rocío, Tomás-Barberán, Francisco A., Ayala, Rosa, Martínez-López, Joaquín, and Linares, María

Abstract

Background: Gut microbiota-derived urolithins may influence multiple myeloma (MM) disease progression and treatment. We analyzed urolithins and their associated microbiota in a retrospective cohort of 45 patients with active MM or premalignant disease using mass spectrometry and 16S rRNA gene sequencing. Results: Patients with detectable levels of urolithin in serum and stool and a higher abundance of urolithin-related microbiota had a better outcome. Analysis of the effects of urolithin A (UroA) treatment ex vivo, in vitro, and in vivo revealed that UroA is cytotoxic against MM cell lines and modulates the cell cycle and mitochondrial activity. Notably, UroA inhibits the proliferation of primary MM cells in vitro and in a xenograft mouse model, improving overall survival. Finally, combination therapy with UroA and bortezomib has a synergistic effect in vitro, even in the presence of bortezomib resistance, and modulates signaling pathways involved in MM development. Conclusions: UroA might be a potential therapeutic agent to halt MM disease progression or to overcome resistance when used in combination. BuEFhn8yrivgG7FAwkY4ST Video Abstract [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results